Organon Faces Lawsuit Over Merger Proxy, Adds $700M Synergy Estimate
OGN has more than doubled off its 52-week low of $5.69 on light trading volume (0.2× avg).
Summary
A New Jersey lawsuit seeks to block the July 23 shareholder vote on Organon's $14/share sale to Sun Pharma, alleging incomplete proxy disclosures. Organon denies the claims but is voluntarily supplementing the proxy with new details, including a preliminary $700M cost synergy estimate and updated 2026 projections: $6.25B revenue, $1.89B adjusted EBITDA, $7.53B net debt, and ~285M fully diluted shares. The lawsuit introduces uncertainty just days before the vote, though the supplemental disclosures may address the plaintiff's concerns. The merger agreement was announced in April at $14.00 per share, and the stock is trading near its 52-week high of $13.60, reflecting market confidence in the deal closing. The July 23 vote is the key event to watch.
At the time of this announcement, OGN was trading at $13.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.